高劑量維他命C癌症| HIGH DOSAGE VITAMIN C THERAPY
High-Dose Vitamin C and Cancer Treatment | Supportive Cancer Therapy
How Can High-Dose Vitamin C Help Cancer Patients?
High-dose Vitamin C
The History and Science of High-Dose Vitamin C
Vitamin C has been used for the prevention of colds and the treatment of scurvy for more than half a century. Dr. Linus Carl Pauling, an American chemist and two-time Nobel Prize laureate, and his research team explored the potential supportive role of high-dose intravenous vitamin C in patients with cancer.【1, 2, 3】 Their observations suggested that, in some cases, high-dose intravenous vitamin C might help support immune function, promote overall well-being, and potentially contribute to improvements in quality of life.【22, 26, 27】
Subsequent laboratory and clinical studies have continued to investigate the effects of high concentrations of vitamin C on cancer cells. Research suggests that vitamin C at pharmacological concentrations may act through several mechanisms, including the generation of hydrogen peroxide (which may selectively affect cancer cells),【18, 19, 20】 modulation of oxidative stress,【20, 25】 immune modulation, and potential synergistic effects when combined with standard cancer treatments.【6, 7, 9, 30, 32】 Further large-scale clinical studies are still needed to confirm its clinical benefits. Therefore, at BMS Clinic, high-dose vitamin C is positioned strictly as a supportive measure and not as a replacement for conventional cancer treatment.- Supporting immune system function
- Providing antioxidant support and potentially helping regulate chronic inflammatory responses
- Supporting collagen synthesis and wound healing
- Managing chronic fatigue and supporting the body’s response to stress
- Providing supportive care alongside the management of diabetes and cardiovascular conditions
The Efficacy of High-Dose Vitamin C as an Adjunctive Therapy
Some Research and Perspectives on High-Dose Vitamin C
Deconstructing the Limitations of Oral Vitamin C
- Individuals with a history of kidney stones 【10, 11, 12】
- Individuals with impaired kidney function or those undergoing dialysis 【10, 11, 12】
- Individuals with haemochromatosis
- Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Intravenous vitamin C
- Oral liposomal vitamin C
- Oral non-liposomal vitamin C
Who might consider consulting a doctor about high-dose Vitamin C (IV Vitamin C)?
- Individuals with tumours
- Cancer survivors
- Individuals with chronic conditions or immune system disorders
- Individuals with inflammatory conditions
- Monitor osmolarity, infusion rate, accompanying nutrients, dietary coordination, and any discomfort that may occur during administration.
- Monitor the vitamin C dosage carefully.
- Some individuals may experience discomfort during high-dose vitamin C administration, particularly if they are not accustomed to the dosage. Possible symptoms include headaches, stomach cramps, dizziness, nausea, and thirst.
The Safety of
High-Dose Vitamin C!
IV Vitamin C
The following individuals should not receive high-dose intravenous vitamin C infusions:
- Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- Patients with kidney failure who require dialysis. 【10, 11, 12】
- Individuals with malnutrition.
- Individuals experiencing dehydration.
Although serious side effects are not commonly reported, the following symptoms may occur:
- Irritation or pain at the intravenous infusion site Reducing the infusion rate may help relieve the discomfort.
- Dry mouth or increased thirst High-dose vitamin C infusion may have a diuretic effect. Drinking adequate amounts of water during or after the infusion may help maintain hydration.
- Potential effects on blood glucose levels and glucose testing Vitamin C has a chemical structure similar to glucose. At high concentrations, it may interfere with certain blood glucose monitoring devices and produce inaccurate readings. This is particularly important for individuals with diabetes, who should inform their medical team and follow appropriate monitoring guidance.
- Fatigue in some individuals
A small number of individuals may feel tired after completing an infusion. If this occurs, adequate rest and monitoring of symptoms are recommended. - Increased bowel activity
High-dose vitamin C may stimulate intestinal activity, potentially resulting in more frequent bowel movements or softer stools.
Research on High-Dose Vitamin C
Summary Regarding High-Dose Vitamin C
- Research on high-dose vitamin C and cancer cells: Vitamin C can break down in the body and generate hydrogen peroxide (H2O2), a type of reactive oxygen species (ROS) capable of damaging tissues and DNA. Studies have also suggested that, compared with normal cells, tumour cells have a weaker ability to eliminate harmful hydrogen peroxide. One area of research into high-dose vitamin C is therefore based on increasing intracellular hydrogen peroxide levels, potentially causing damage to cancer cells and triggering apoptosis (programmed cell death). 【18】
- Some human clinical trials suggest that high-dose vitamin C may help alleviate certain chemotherapy-related side effects, including fatigue and nausea, while potentially improving appetite and quality of life. 【9, 29, 31】
- Research indicates that oral vitamin C cannot achieve the pharmacological blood concentrations associated with certain anticancer mechanisms. Intravenous administration is required to achieve concentrations of approximately 20 mM. 【18, 28】
- Some laboratory studies have found that high-dose vitamin C may affect the proliferation of cancer cell lines in vitro, including prostate, pancreatic, liver, colorectal, mesothelioma, and neuroblastoma cells. 【18, 30】
- Some animal studies have found that high-dose vitamin C may slow tumour cell growth. 【20】
- Two human studies have suggested that intravenous high-dose vitamin C may help improve quality of life in patients with advanced cancer and may reduce certain cancer treatment-related side effects, such as nausea and vomiting. 【29, 31】
FAQ – High-Dose Vitamin C Therapy
Frequently Asked Questions
What is the cost of high-dose vitamin C?
The cost of high-dose vitamin C varies across different countries. In Hong Kong, the price ranges from HK$2,500 to HK$3,500 per session (varies by dosage), typically charged in a treatment course of 10-session.
What should be noted when receiving intravenous high-dose vitamin C injections?
Due to the fact that the administration of high-dose vitamin C injections is a procedure that requires supervision by healthcare professionals, it must be conducted by qualified medical personnel to ensure the accuracy of infusion and the safety of the process.
Conventional treatment vs. high-dose vitamin C therapy?
High-dose vitamin C Therapy cannot replace traditional/conventional mainstream treatments such as chemotherapy, radiation therapy, cellular therapy, or immunotherapy. It is important to consult with your doctor to plan an appropriate adjunctive treatment plan and to coordinate with the treatment plan of mainstream conventional medicine.
Protocol of high dosage vitamin C?
The recommended dosage, duration, and frequency of treatment may vary depending on the individual’s condition and tolerance.
Typically, a single infusion of high-dose vitamin C ranges from 300ml to 500ml, and the administration time is approximately 60 to 90 minutes.
After diagnosis, the doctor will advise on the appropriate dosage, duration, and frequency of treatment.
Benefits of high-dose vitamin C?
High-dose vitamin C therapy can enhance immune function, and there are studies suggesting a potential reduction in the risk of developing cancer or its spread (further research is needed). It may also contribute to improving the effectiveness of chemotherapy and radiation therapy (further research is needed). Cancer patients, individuals in recovery, those with chronic diseases, or immune system disorders can consult with healthcare professionals and doctors to learn more about this treatment method.
Can high-dose IV Vitamin C extend survival for cancer patients?
Some overseas clinical studies suggest that high-dose IV Vitamin C, when used as supportive care alongside standard chemotherapy, may offer potential survival benefits in specific cancers (e.g., advanced pancreatic cancer). For example, a 2024 randomized phase II trial from the University of Iowa (a small study involving 34 patients with late-stage metastatic pancreatic cancer) reported that adding high-dose IV Vitamin C to chemotherapy extended median overall survival from about 8 months to 16 months, while also improving quality of life and reducing certain side effects. However, this is a single phase II result and has not been confirmed by large-scale phase III trials or broad consensus for reliably extending survival across all cancer types or patient groups. Hong Kong currently has no official research, clinical trials, or guidelines endorsing this as a standard approach for survival extension. Reviews from sources like the NCI and Mayo Clinic note possible benefits in treatment tolerance, but there is no evidence it cures cancer or dramatically improves prognosis on its own. At BMS Clinic, all IVC sessions are strictly supervised by registered doctors, with pre-screening (e.g., kidney function, G6PD deficiency) and coordination with your primary oncologist (Upon request) to ensure safety and avoid conflicts. It is suitable only as complementary support, not a replacement for mainstream treatment. Appropriate for patients in Cheung Sha Wan and Hong Kong—bring your medical records for a consultation: +852 2370 3001 or WhatsApp +852 9277 7808.
Is high-dose IV Vitamin C safe for cancer treatment? What are the potential side effects?
Under professional medical supervision, high-dose IV Vitamin C is generally safe and well-tolerated. Clinical trials (e.g., Mayo Clinic, NCI, and recent pancreatic cancer studies) show most patients experience no serious adverse events. Common mild side effects include minor discomfort at the IV site, dry mouth, slight nausea, or temporary blood sugar fluctuations (as IVC can interfere with some glucose tests). We pre-screen for risks like kidney function or G6PD deficiency to prevent complications. At BMS Clinic in Cheung Sha Wan, Hong Kong, we follow strict safety protocols for outpatient sessions. Suitable for most patients after individual assessment.
Does high dose vitamin C cure cancer?
No, high-dose vitamin C does not cure cancer on its own, and there is no reliable evidence that it serves as a standalone cure for any type of cancer.
High-dose intravenous vitamin C (HDIVC, also known as pharmacological ascorbate) is best studied and utilized as a supportive adjunctive therapy in integrative oncology. Many experienced integrative doctors incorporate it alongside standard cancer treatments (such as chemotherapy, radiation, or immunotherapy) to help enhance treatment tolerance, support quality of life, and potentially improve clinical outcomes for suitable patients.
Recent evidence is encouraging in this supportive role:
- A randomized Phase II clinical trial published in Redox Biology (2024) from the University of Iowa showed that adding high-dose IV vitamin C (75 g, three times per week) to standard chemotherapy (gemcitabine + nab-paclitaxel) in patients with stage IV metastatic pancreatic cancer nearly doubled median overall survival — from approximately 8 months with chemotherapy alone to 16 months with the combination. Progression-free survival also improved, and the addition was well tolerated without increasing severe side effects or harming quality of life.
Other Phase I/II studies and reviews have similarly reported benefits when HDIVC is used supportively, including:
- Reduced fatigue, pain, and nausea
- Better tolerance to chemotherapy and radiation
- Potential protective effects on healthy tissues while exerting selective oxidative stress on cancer cells
Integrative doctors with expertise in this area often emphasize proper patient selection, precise dosing, and integration with conventional care to maximize these supportive benefits. Larger Phase III trials are ongoing to further clarify its role across different cancer types.
Key takeaway: High-dose IV vitamin C is not a cancer cure, but when thoughtfully incorporated by experienced integrative practitioners as part of a comprehensive plan, it shows promise as a safe, well-tolerated supportive option that may help improve survival and quality of life in certain settings. It should always complement — never replace — standard oncology care. Patients are encouraged to discuss it openly with a qualified doctor for personalized guidance.
Why does high dose IV vitamin C work for some cancer patients but not others?
The effectiveness of high-dose intravenous vitamin C (HDIVC) as a supportive therapy can vary noticeably between patients. This difference does not mean the approach is ineffective overall; rather, it often reflects how precisely the therapy is tailored to the individual — an area where experienced integrative doctors can make a meaningful difference.
Skilled integrative oncology practitioners focus on optimizing several key factors to improve the likelihood of benefit:
Precise Dosage and Plasma Levels Benefits are linked to achieving high pharmacological blood concentrations (typically >10 mM), which only intravenous administration can reliably deliver. Integrative doctors carefully calculate and monitor doses to ensure therapeutic levels are reached safely.
Frequency, Duration, and Timing Effective protocols commonly involve 2–3 infusions per week over an extended period, carefully timed with other treatments for better synergy.
Integration with Standard Therapies Many integrative doctors report stronger supportive effects when HDIVC is thoughtfully combined with specific chemotherapies, radiation, or immunotherapy, potentially enhancing tolerance and outcomes while helping protect normal cells.
Comprehensive Patient Assessment Experienced practitioners perform thorough screening (e.g., G6PD deficiency, kidney function) and consider the patient’s overall health, cancer stage, and individual biology.
Personalized Sensitivity Profiling One helpful emerging tool used in some integrative settings is Circulating Tumor Cell (CTC) functional sensitivity testing. This lab analysis exposes a patient’s own circulating cancer cells to high-dose vitamin C (and other natural substances) to assess likely response.
- High sensitivity on the test may indicate a greater chance of benefit from HDIVC.
- Low sensitivity helps guide the doctor toward more suitable supportive options.
This type of personalization allows integrative doctors to move beyond generic approaches and design regimens better matched to the patient’s unique cancer biology.
Bottom line: When administered with attention to detail by integrative doctors experienced in adjunctive therapies, high-dose IV vitamin C can provide meaningful supportive benefits for many patients — including better quality of life and, in some cases, improved survival metrics as seen in recent trials. Results are more consistent when the therapy is precisely executed and integrated into a broader, individualized care plan.
Important Safety Note: Under proper medical supervision with appropriate screening, HDIVC has demonstrated a good safety profile in clinical studies. It is intended as a complementary supportive approach, not a replacement for conventional cancer treatment. The best outcomes often occur through close collaboration between the patient’s oncologist and an experienced integrative doctor.
Disclaimer: This information is for educational purposes only and is not medical advice. Treatment decisions, including the use of any integrative therapies, should always be made in consultation with qualified healthcare professionals based on your individual situation.
References
- 【1】 Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974;9:285–315. doi:10.1016/0009-2797(74)90019-2.
- 【2】 Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976;73(10):3685–3689. doi:10.1073/pnas.73.10.3685.
- 【3】 Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978;75(9):4538–4542. doi:10.1073/pnas.75.9.4538.
- 【4】 Riordan HD, Casciari JJ, González MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005;24:269–276.
- 【5】 Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19(11):1969–1974. doi:10.1093/annonc/mdn377.
- 【6】 Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. doi:10.1371/journal.pone.0029794.
- 【7】 Welsh JL, Wagner BA, van’t Erve TJ, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013;71(3):765–775. doi:10.1007/s00280-013-2070-8.
- 【8】 Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(1):139–146. doi:10.1007/s00280-013-2179-9.
- 【9】 Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18. doi:10.1126/scitranslmed.3007154.
- 【10】 Lawton JM, Conway LT, Crosson JT, Smith CL, Abraham PA. Acute oxalate nephropathy after massive ascorbic acid administration. Arch Intern Med. 1985;145(5):950–951. doi:10.1001/archinte.1985.00360050220044.
- 【11】 Wong K, Thomson C, Bailey RR, McDiarmid S, Gardner J. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med. 1994;24(4):410–411. doi:10.1111/j.1445-5994.1994.tb01477.x.
- 【12】 Cossey LN, Rahim F, Larsen CP. Oxalate nephropathy and intravenous vitamin C. Am J Kidney Dis. 2013;61(6):1032–1035. doi:10.1053/j.ajkd.2013.01.025.
- 【13】 Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol. 1999;10(4):840–845.
- 【14】 Gerster H. No contribution of ascorbic acid to renal calcium oxalate stones. Ann Nutr Metab. 1997;41(5):269–282. doi:10.1159/000177954.
- 【15】 Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol. 1996;155(6):1847–1851.
- 【16】 Creagan ET, Moertel CG, O’Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979;301(13):687–690. doi:10.1056/NEJM197909273011303.
- 【17】 Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985;312(3):137–141. doi:10.1056/NEJM198501173120301.
- 【18】 Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005;102(38):13604–13609. doi:10.1073/pnas.0506390102.
- 【19】 Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A. 2007;104(21):8749–8754. doi:10.1073/pnas.0702854104.
- 【20】 Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008;105(32):11105–11109. doi:10.1073/pnas.0804226105.
- 【21】 Mikirova N, Hunnunghake R, Scimeca RC, et al. High-dose intravenous vitamin C treatment of a child with neurofibromatosis type 1 and optic pathway glioma: a case report. Am J Case Rep. 2016;17:774–781. doi:10.12659/AJCR.899754.
- 【22】 Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl. 1982;23:103–113.
- 【23】 Zhao H, Zhu H, Huang J, et al. The synergy of vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res. 2018;66:1–7. doi:10.1016/j.leukres.2017.12.009.
- 【24】 Gunes-Bayir A, Kiziltan HS. Palliative vitamin C application in patients with radiotherapy-resistant bone metastases: a retrospective study. Nutr Cancer. 2015;67(6):921–925. doi:10.1080/01635581.2015.1055366.
- 【25】 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. O2- and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell. 2017;31(4):487.e8–500.e8. doi:10.1016/j.ccell.2017.02.018.
- 【26】 Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006;174(7):937–942. doi:10.1503/cmaj.050346.
- 【27】 Raymond YC, Glenda CS, Meng LK. Effects of high doses of vitamin C on cancer patients in Singapore: nine cases. Integr Cancer Ther. 2016;15(2):197–204. doi:10.1177/1534735415622010.
- 【28】 Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140(7):533–537. doi:10.7326/0003-4819-140-7-200404060-00010.
- 【29】 Vollbracht C, Schneider B, Leendert V, et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25(6):983–990.
- 【30】 Espey MG, Chen P, Chalmers B, et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011;50(11):1610–1619. doi:10.1016/j.freeradbiomed.2011.03.007.
- 【31】 Takahashi H, Mizuno H, Yanagisawa A. High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe. 2012;1:49–53. doi:10.1016/j.pmu.2012.05.008.
- 【32】 Bodeker KL, Smith BJ, Berg DJ, et al. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biol. 2024;77:103375. doi:10.1016/j.redox.2024.103375.